BRPI0511448A - anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências - Google Patents

anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências

Info

Publication number
BRPI0511448A
BRPI0511448A BRPI0511448-9A BRPI0511448A BRPI0511448A BR PI0511448 A BRPI0511448 A BR PI0511448A BR PI0511448 A BRPI0511448 A BR PI0511448A BR PI0511448 A BRPI0511448 A BR PI0511448A
Authority
BR
Brazil
Prior art keywords
tnf
high affinity
alpha antibodies
antibody
generation method
Prior art date
Application number
BRPI0511448-9A
Other languages
English (en)
Inventor
Roberto Crea
Arvind Rajpal
Toshi Takeuchi
Guido Cappuccilli
Jennifer Jones
Original Assignee
Bioren Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioren Inc filed Critical Bioren Inc
Publication of BRPI0511448A publication Critical patent/BRPI0511448A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTICORPOS ANTI-TNF-ALFA DE ALTA AFINIDADE, MéTODO PARA A GERAçãO DOS MESMOS E BIBLIOTECA DE SEQüêNCIAS. A presente invenção refere-se a um anticorpo anti-TNF-<244> humano isolado, ou parte de ligação a antígeno do mesmo, contendo pelo menos uma cadeia de anticorpo V~ L~ ou V~ H~ de alta afinidade que é eficaz, quando substituída pela cadeia V~ L~ ou V~ H~ correspondente do anticorpo anti-TNF-<244> scFv que apresenta a seqüência SEQ ID NO: 1, para ligar-se a TNF-<244> humano com uma taxa constante K~ off~ que é pelo menos 1,5 vez menor que aquela do anticorpo que apresenta SEQ ID NO: 1, quando determinada sob condições idênticas.
BRPI0511448-9A 2004-07-06 2005-07-06 anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências BRPI0511448A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58648704P 2004-07-06 2004-07-06
PCT/US2005/023957 WO2006014477A1 (en) 2004-07-06 2005-07-06 HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD

Publications (1)

Publication Number Publication Date
BRPI0511448A true BRPI0511448A (pt) 2007-12-26

Family

ID=34975191

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511448-9A BRPI0511448A (pt) 2004-07-06 2005-07-06 anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências

Country Status (6)

Country Link
US (1) US20060024308A1 (pt)
EP (1) EP1769003A1 (pt)
BR (1) BRPI0511448A (pt)
CA (1) CA2573259A1 (pt)
MX (1) MX2007000104A (pt)
WO (1) WO2006014477A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
CA2634080A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
JP5259423B2 (ja) * 2006-02-01 2013-08-07 セファロン・オーストラリア・ピーティーワイ・リミテッド ドメイン抗体構築物
AR066016A1 (es) * 2007-04-11 2009-07-15 Alcon Res Ltd Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
EP2242843B1 (en) * 2007-12-31 2015-05-27 XOMA Technology Ltd. Methods and materials for targeted mutagenesis
EP2799450A1 (en) 2007-12-31 2014-11-05 Bayer Intellectual Property GmbH Antibodies to TNFalpha
IT1394281B1 (it) * 2009-01-19 2012-06-06 Zardi Processo per la produzione di proteine di fusione polivalenti e polispecifiche utilizzando come struttura portante l'uteroglobina e prodotti cosi' ottenuti.
WO2010105446A1 (zh) * 2009-03-20 2010-09-23 上海宏源生物技术有限公司 抗人肿瘤坏死因子受体α单抗及其应用
RU2595379C2 (ru) * 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
CN101875694B (zh) * 2009-04-28 2014-04-02 中国医学科学院基础医学研究所 TNFα的抗体及其用途
CA2773483A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
CN102167741B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
AU2011237679B2 (en) 2010-04-07 2014-11-06 Abbvie Inc. TNF-alpha binding proteins
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
RU2014120755A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммуносвязующие агенты, направленные против tnf
CA2853114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
EP3122777B1 (en) 2014-03-26 2020-12-23 Cell Medica Switzerland AG Binding members to tnf alpha
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
WO2018227604A1 (en) * 2017-06-16 2018-12-20 Huawei Technologies Co., Ltd. Methods and apparatus for polar encoding
CA3093422A1 (en) * 2018-03-19 2019-09-26 Bioventures, Llc Periostin antibodies and methods of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015581A1 (en) * 1990-04-05 1991-10-17 Roberto Crea Walk-through mutagenesis
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
DE60316547T2 (de) * 2002-04-17 2008-07-03 Bioren, Inc., San Carlos Doping bei der walk-through-mutagenese
US20050136428A1 (en) * 2003-06-27 2005-06-23 Roberto Crea Look-through mutagenesis

Also Published As

Publication number Publication date
MX2007000104A (es) 2007-07-18
CA2573259A1 (en) 2006-02-09
EP1769003A1 (en) 2007-04-04
WO2006014477A9 (en) 2006-03-16
US20060024308A1 (en) 2006-02-02
WO2006014477A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
BRPI0511448A (pt) anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
DK1139101T3 (da) Immunobestemmelse for C-reaktivt protein
ATE480562T1 (de) Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
BRPI0409269A (pt) anticorpo modificado da classe igg e método de produção do mesmo
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
NZ701444A (en) Antibodies to matrix metalloproteinase 9
NZ607711A (en) Antibodies directed to her-3 and uses thereof
RS53058B (en) SP35 ANTIBODIES AND THEIR APPLICATIONS
HK1134303A1 (en) Fab fragment libraries and methods for their use fab
NZ585622A (en) Hepatitis c virus antibodies
RS52439B (en) HUMAN ANTIBODIES TO THE HUMAN DELTA SIMILAR LIGAND 4
HRP20161398T1 (hr) Anti-idiotip-protutijelo protiv protutijela koje je protiv amiloid-beta-peptida
HK1200854A1 (en) Methods for antibody engineering
BRPI0611714A2 (pt) proteÍnas de ligaÇço a il-12/p40
NZ599683A (en) Anti-ilt7 antibody
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
DK1697421T3 (da) Bispecifikke antistoffer
RS53819B1 (en) ANTI-ACTIVIN ANTIBODIES AND THEIR APPLICATIONS
EA200870072A1 (ru) ПРОТИВОВОСПАЛИТЕЛЬНЫЕ dAb
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
NZ594682A (en) Fully human antibodies specific to cadm1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.